NCT07222891 Impact of Smell Testing on Health Outcomes
| NCT ID | NCT07222891 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Monell Chemical Senses Center |
| Condition | Olfactory Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 1,000 participants in total. It began in 2026-05-29 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.
Eligibility Criteria
Inclusion Criteria: \- Can read and understand English and have access to a reliable internet connection and a smart device or computer for the duration of the experimental sessions, unless they are part of community events in which smart devices are provided Exclusion Criteria: \- Known intolerance or allergy to any of the odor stimuli used
Contact & Investigator
Valentina Parma
PRINCIPAL INVESTIGATOR
Monell Chemical Senses Center
Frequently Asked Questions
Who can join the NCT07222891 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, studying Olfactory Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07222891 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07222891 currently recruiting?
Yes, NCT07222891 is actively recruiting participants. Contact the research team at vparma@monell.org for enrollment information.
Where is the NCT07222891 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07222891 clinical trial?
NCT07222891 is sponsored by Monell Chemical Senses Center. The principal investigator is Valentina Parma at Monell Chemical Senses Center. The trial plans to enroll 1,000 participants.